Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants of sensitivity to these agents, we analyzed PIK3CA-mutant cancer genomes and observed the presence of multiple PIK3C...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Science
Autores principales: Vasan, Neil, Razavi, Pedram, Johnson, Jared L., Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T., Taylor, Barry S., Dickler, Maura N., Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L., Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R., Friedman, Lori S., Cantley, Lewis C., Scaltriti, Maurizio, Baselga, José
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7173400/
https://ncbi.nlm.nih.gov/pubmed/31699932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.aaw9032
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares